Noel Rodríguez-Pérez

Noel Rodríguez-Pérez

Auto-generated profile, based on publicly available information

Noel Rodríguez-Pérez

Universidad Autónoma de Tamaulipas, Tamaulipas

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2020 in World Allergy Organization Journal
Verified
Journal Article
Open access
CSCentro de Excelencia en Asma y Alergia Erlinda Larenas S.C.
Centro de Excelencia en Asma y Alergia Erlinda Larenas S.C.
NRNoel Rodríguez-Pérez
Noel Rodríguez-Pérez
AAAlfredo Arias-Cruz
Alfredo Arias-Cruz
MBMaría Virginia Blandón-Vijil
María Virginia Blandón-Vijil
BRBlanca Estela Del Rio-Navarro
Blanca Estela Del Rio-Navarro
MRMaría Isabel Rojo-Gutiérrez
María Isabel Rojo-Gutiérrez
In the light of the current COVID-19 pandemic, during which the world is confronted with a new, highly contagious virus that suppresses innate immunity as one of its initial virulence mechanisms, thus escaping from the first-line human defense mechanisms, enhancing innate immunity seems a good preventive strategy. Without the intention to write an official systematic review, but more to give an overview of possible strategies, in this review article we discuss several interventions that might stimulate innate immunity and thus our defense against (viral) respiratory tract infections. Some of these interventions can also stimulate the adaptive T- and B-cell responses, but our main focus is on the innate part of immunity. We divide the reviewed interventions in: 1) lifestyle related (exercise, >7 hours sleep, forest walking, meditation/mindfulness, vitamin supplementation); 2) Non-specific immune stimulants (letting fever advance, bacterial vaccines, probiotics, dialyzable leukocyte extract, pidotimod) and 3) specific vaccines with heterologous effect (BCG vaccine, mumps-measles-rubeola vaccine, i.e.). For each of these interventions we briefly comment on their definition, possible mechanisms and evidence of clinical efficacy or lack of it, especially focusing on respiratory tract infections, viral infections and eventually a reduced mortality in severe respiratory infections in the intensive care unit. At the end a summary table demonstrates the best trials supporting (or not) clinical evidence. Several interventions have some degree of evidence for enhancing the innate immune response and thus conveying possible benefit, but specific trials in COVID-19 should be conducted to support solid recommendations.

26 February 2021 in Current Allergy and Asthma Reports
Verified
Journal Article
Closed access
PDF file
CSCentro de Excelencia en Asma y Alergia Erlinda Larenas S.C.
Centro de Excelencia en Asma y Alergia Erlinda Larenas S.C.
JLJorge Luna-Pech
Jorge Luna-Pech
ENElsy Maureen Navarrete-Rodríguez
Elsy Maureen Navarrete-Rodríguez
NRNoel Rodríguez-Pérez
Noel Rodríguez-Pérez
AAAlfredo Arias-Cruz
Alfredo Arias-Cruz
MTMirna Eréndira Toledo-Bahena
Mirna Eréndira Toledo-Bahena

15 June 2019 in Revista Alergia México
Verified
Journal Article
Open access
PDF file
CSCentro de Excelencia en Asma y Alergia Erlinda Larenas S.C.
Centro de Excelencia en Asma y Alergia Erlinda Larenas S.C.
JLJorge A. Luna-Pech
Jorge A. Luna-Pech
NRNoel Rodríguez-Pérez
Noel Rodríguez-Pérez
MRMónica Rodríguez-González
Mónica Rodríguez-González
AAAlfredo Arias-Cruz
Alfredo Arias-Cruz
MMMiguel Alejandro Medina-Ávalos
Miguel Alejandro Medina-Ávalos
Background: In Mexico, allergen immunotherapy (AIT) and immunotherapy with hymenoptera venom (VIT) is traditionally practiced combining aspects of the European and American school. In addition, both types of extracts (European and American) are commercially available in Mexico. Moreover, for an adequate AIT/VIT a timely diagnosis is crucial. Therefore, there is a need for a widely accepted, up-to-date national immunotherapy guideline that covers diagnostic issues, indications, dosage, mechanisms, adverse effects and future expectations of AIT (GUIMIT 2019).Method: With nationwide groups of allergists participating, including delegates from postgraduate training-programs in Allergy/Immunology-forming, the guideline document was developed according to the ADAPTE methodology: the immunotherapy guidelines from European Academy of Allergy and Clinical Immunology, German Society for Allergology and Clinical Immunology, The American Academy of Allergy, Asthma and Immunology and American College of Allergy, Asthma, and Immunology were selected as mother guidelines, as they received the highest AGREE-II score among international guidelines available; their evidence conforms the scientific basis for this document.Results: GUIMIT emanates strong or weak (suggestions) recommendations about practical issues directly related to in vivo or in vitro diagnosis of IgE mediated allergic diseases and the preparation and application of AIT/VIT and its adverse effects. GUIMIT finishes with a perspective on AIT modalities for the future. All the statements were discussed and voted on until > 80 % consensus was reached.Conclusion: A wide and diverse group of AIT/VIT experts issued transculturized, evidence-based recommendations and reached consensus that might improve and standardize AIT practice in Mexico.

1 August 2020 in World Allergy Organization Journal
Verified
Journal Article
Open access
CSCentro de Excelencia en Asma y Alergia Erlinda Larenas S.C.
Centro de Excelencia en Asma y Alergia Erlinda Larenas S.C.
NRNoel Rodríguez-Pérez
Noel Rodríguez-Pérez
JLJorge A. Luna-Pech
Jorge A. Luna-Pech
MRMónica Rodríguez-González
Mónica Rodríguez-González
MBMaría Virginia Blandón-Vijil
María Virginia Blandón-Vijil
MMMiguel Alejandro Medina-Ávalos
Miguel Alejandro Medina-Ávalos
Allergen immunotherapy (AIT) has a longstanding history and still remains the only disease-changing treatment for allergic rhinitis and asthma. Over the years 2 different schools have developed their strategies: the United States (US) and the European. Allergen extracts available in these regions are adapted to local practice. In other parts of the world, extracts from both regions and local ones are commercialized, as in Mexico. Here, local experts developed a national AIT guideline (GUIMIT 2019) searching for compromises between both schools. Using ADAPTE methodology for transculturizing guidelines and AGREE-II for evaluating guideline quality, GUIMIT selected 3 high-quality Main Reference Guidelines (MRGs): the European Academy of Allergy, Asthma and Immunology (EAACI) guideines, the S2k guideline of various German-speaking medical societies (2014), and the US Practice Parameters on Allergen Immunotherapy 2011. We formulated clinical questions and based responses on the fused evidence available in the MRGs, combined with local possibilities, patient's preference, and costs. We came across several issues on which the MRGs disagreed. These are presented here along with arguments of GUIMIT members to resolve them. GUIMIT (for a complete English version, Supplementary data) concluded the following: Related to the diagnosis of IgE-mediated respiratory allergy, apart from skin prick testing complementary tests (challenges, in vitro testing and molecular such as species-specific allergens) might be useful in selected cases to inform AIT composition. AIT is indicated in allergic rhinitis and suggested in allergic asthma (once controlled) and IgE-mediated atopic dermatitis. Concerning the correct subcutaneous AIT dose for compounding vials according to the US school: dosing tables and formula are given; up to 4 non-related allergens can be mixed, refraining from mixing high with low protease extracts. When using European extracts: the manufacturer's indications should be followed; in multi-allergic patients 2 simultaneous injections can be given (100% consensus); mixing is discouraged. In Mexico only allergoid tablets are available; based on doses used in all sublingual immunotherapy (SLIT) publications referenced in MRGs, GUIMIT suggests a probable effective dose related to subcutaneous immunotherapy (SCIT) might be: 50–200% of the monthly SCIT dose given daily, maximum mixing 4 allergens. Also, a table with practical suggestions on non-evidence-existing issues, developed with a simplified Delphi method, is added. Finally, dissemination and implementation of guidelines is briefly discussed, explaining how we used online tools for this in Mexico. Countries where European and American AIT extracts are available should adjust AIT according to which school is followed.

29 April 2020 in Revista Alergia México
Verified
Journal Article
Open access
PDF file
LRLorena Rangel-Garza
Lorena Rangel-Garza
CSCentro de Excelencia en Asma y Alergia Erlinda Larenas S.C.
Centro de Excelencia en Asma y Alergia Erlinda Larenas S.C.
NRNoel Rodríguez-Pérez
Noel Rodríguez-Pérez
JOJosé Antonio Ortega-Martell
José Antonio Ortega-Martell
JOJosé Joel Oyoqui-Flores
José Joel Oyoqui-Flores
Background: There are different guidelines for the diagnosis of allergic diseases and the application of allergen immunotherapy (AIT).Objective: To describe how Mexican allergists diagnose and treat respiratory and food allergies with AIT.Methods: 227 allergists who attended an immunotherapy symposium were surveyed; the topics investigated were the daily practices in the diagnosis of respiratory and food allergies, as well as ways to apply AIT.Results: The surveyed allergists use skin prick tests for the diagnosis of both respiratory and food allergies in 100 % and 87.7 % of their cases respectively; in vitro diagnosis through serum specific IgE in 55.5 % and 63 %, and molecular diagnostics in 14.1% and 13.2 %. For aeroallergens, 81 % prescribe subcutaneous AIT, 77.9 % use liquid sublingual AIT, and 1.8 % prefer SLIT in tablets; however, 45 % indicated that they would use tablets in the future. Regarding food allergens, most respondents did not prescribe AIT; however, 55% of them are interested in oral AIT and 59% of them are interested in sublingual AIT.Conclusions: Generally, the diagnosis and treatment of allergic diseases are carried out according to international guidelines; besides, the interviewed allergists expressed flexibility to adopt new schemes.

29 June 2020 in Revista Alergia México
Verified
Journal Article
Open access
PDF file
CSCentro de Excelencia en Asma y Alergia Erlinda Larenas S.C.
Centro de Excelencia en Asma y Alergia Erlinda Larenas S.C.
BRBlanca Estela Del Rio-Navarro
Blanca Estela Del Rio-Navarro
JLJorge Luna-Pech
Jorge Luna-Pech
ENElsy Maureen Navarrete-Rodríguez
Elsy Maureen Navarrete-Rodríguez
CPCésar Fireth Pozo-Beltrán
César Fireth Pozo-Beltrán
EMEric A. Martínez-Infante
Eric A. Martínez-Infante
The current COVID-19 pandemic has represented a major challenge for society and the medical community, not only because of its high contagion but also because of the variability of clinical manifestations and its unpredictable behavior under different health contexts. Given this, specific preventive measures are relevant to avoid or reduce infections between patients and health unit personnel, considering that the presymptomatic period during which the infected individual can already transmit the virus varies between five and six or up to 14 days, according to data from the World Health Organization. In addition, an infected patient can be asymptomatic, even some people after having suffered COVID-19 can continue to shed virus for a few more days after recovering.